EMAIL THIS PAGE TO A FRIEND

Clinical science (London, England : 1979)

Deficiency of adipocyte fatty-acid-binding protein alleviates myocardial ischaemia/reperfusion injury and diabetes-induced cardiac dysfunction.


PMID 26186740

Abstract

Clinical evidence shows that circulating levels of adipocyte fatty-acid-binding protein (A-FABP) are elevated in patients with diabetes and closely associated with ischaemic heart disease. Patients with diabetes are more susceptible to myocardial ischaemia/reperfusion (MI/R) injury. The experiments in the present study investigated the role of A-FABP in MI/R injury with or without diabetes. Non-diabetic and diabetic (streptozotocin-induced) A-FABP knockout and wild-type mice were subjected to MI/R or sham intervention. After MI/R, A-FABP knockout mice exhibited reductions in myocardial infarct size, apoptotic index, oxidative and nitrative stress, and inflammation. These reductions were accompanied by an improved left ventricular function compared with the relative controls under non-diabetic or diabetic conditions. After diabetes induction, A-FABP knockout mice exhibited a preserved cardiac function compared with that in wild-type mice. Endothelial cells, but not cardiomyocytes, were identified as the most likely source of cardiac A-FABP. Cardiac and circulating A-FABP levels were significantly increased in mice with diabetes or MI/R. Diabetes-induced superoxide anion production was significantly elevated in wild-type mice, but diminished in A-FABP knockout mice, and this elevation contributed to the exaggeration of MI/R-induced cardiac injury. Phosphorylation of endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) were enhanced in both diabetic and non-diabetic A-FABP knockout mice after MI/R injury, but diminished in wild-type mice. The beneficial effects of A-FABP deficiency on MI/R injury were abolished by the NOS inhibitor N(G)-nitro-L-arginine methyl ester. Thus, A-FABP deficiency protects mice against MI/R-induced and/or diabetes-induced cardiac injury at least partially through activation of the eNOS/NO pathway and reduction in superoxide anion production.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1408988
Anti-FABP4 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA002188
Anti-FABP4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2100743
Anti-FABP4 antibody produced in rabbit, affinity isolated antibody
SAB2104636
Anti-FABP4 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB4300636
Anti-FABP4 antibody produced in rabbit, affinity isolated antibody
SAB1410359
Anti-FABP4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1410360
Anti-FABP4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB3700293 Anti-goat IgG (H+L) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB3700604 Anti-Rat IgG (H+L) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
WH0002167M1
Monoclonal Anti-FABP4 antibody produced in mouse, clone 2H3-1G10, purified immunoglobulin, buffered aqueous solution
SAB1403801
Monoclonal Anti-FABP4 antibody produced in mouse, clone 4G1, purified immunoglobulin, buffered aqueous solution
SAB1408986
Monoclonal Anti-FABP4 antibody produced in mouse, clone 3G1, purified immunoglobulin, buffered aqueous solution
SAB1408987 Monoclonal Anti-FABP4 antibody produced in mouse, clone 2F12-1B11, ascites fluid, solution